What Happened

Tango Therapeutics announced a 14% headcount reduction via an SEC filing, with most cuts coming from its research group. The biotech is deprioritizing novel target discovery to concentrate resources on advancing its lead candidate vopimetostat in a Phase 3 registrational trial for MTAP-deleted PDAC.

Who Is Affected

The majority of the ~14% workforce reduction targets employees in Tango's research group. The company is retaining clinical development and regulatory teams needed to support its Phase 3 trial and potential regulatory filings. External partners like Revolution Medicines may also see changes in supply agreements.

Market Impact

• Tango's stock dropped 16.4% on the data release, possibly reflecting a decline in ORR from 92% to 82% between data cuts.
• William Blair analysts highlighted the cross-trial advantage over Rasonque monotherapy and noted nine-month PFS trends are 'holding up.'
• Tango lacks a supply agreement with Revolution Medicines for the Phase 3 trial, creating negotiation risk.

What to Watch

Tango plans to start a registrational Phase 3 trial in frontline PDAC in H1 2027, with discussions with regulators for accelerated approval in second-line setting. Watch for updates on supply agreements, additional Phase 3 partners, and data from the ongoing combination trial.

Related coverage

• FDA approves Revolution Medicines' daraxonrasib for advanced pancreatic cancer
• EyePoint to halve workforce, end pivotal wet AMD trials early after second Phase 3 fail
• GSK plans 1,200+ layoffs at Belgium sites as $2.5B restructure gains momentum
• GSK to lay off over 1,200 roles in Belgium as cost-saving program picks up steam